Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Antibiotics

New compound could improve treatment of lung infection in cystic fibrosis patients

Tomás Sou, a researcher at the Department of Pharmacy, Uppsala University in Sweden, presented the study at the International Pharmaceutical Federation's Pharmaceutical Sciences World Congress 2017

Source: Julia Robinson / The Pharmaceutical Journal

Tomás Sou, a researcher at the Department of Pharmacy, Uppsala University in Sweden, presented the study at the International Pharmaceutical Federation’s Pharmaceutical Sciences World Congress 2017 in Stockholm, Sweden.

Scientists have developed a new compound that could improve the quality of life of cystic fibrosis patients by increasing the effectiveness of antibiotics in tackling chronic lung infection caused by Pseudomonas aeruginosa.

According to research, presented at the International Pharmaceutical Federation’s Pharmaceutical Sciences World Congress on 22 May 2017[1], the compound — called a quorum sensing inhibitor (QSI) — interrupts the communication pathways, or quorum sensing, between P. aeruginosa bacterial cells, resulting in reduced virulence and decreased tolerance to antibiotics.

“This research could ultimately improve the quality of life for these patients and, potentially, others,” says Tomás Sou, a researcher at the Department of Pharmacy, Uppsala University in Sweden, who presented the study at the conference.

P. aeruginosa infections are also a concern in hospitals, particularly for patients who have been in hospital for more than a week. These infections can be life-threatening. Our work could eventually also have relevance for these people.”

Around 80% of CF patients suffer from chronic lung infections caused by P. aeruginosa. These infections are commonly treated with antibiotics, such as tobramycin, but with varying degrees of success as P. aeruginosa can develop resistance to antibiotics by forming a biofilm. Consequently, P. aeruginosa infection is associated with a rapid decline in lung function and increased morbidity and mortality.

With this knowledge, the researchers developed a compound that could inhibit the quorum sensing communication between bacteria cells that enables biofilm formation and consequently reduce antibiotic resistance.

The QSI was delivered in combination with tobramycin as a liquid aerosol formulation directly into the lungs of a rat model of chronic P. aeruginosa. The result was a synergistic effect between the QSI and tobramycin whereby the bacteria was sensitised to the antibiotic resulting in fewer P. aeruginosa biofilm colonies.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202823

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Tomás Sou, a researcher at the Department of Pharmacy, Uppsala University in Sweden, presented the study at the International Pharmaceutical Federation's Pharmaceutical Sciences World Congress 2017

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.